Короткий опис(реферат):
There are many reports in the literature about the critical role of the immune system in protecting the
body against foreign agents. However, the role of immune status in the association of mycobacteriosis and
fasciolosis has not been studied. The work aimed to investigate the effect of butaselmevit and closaverm A
on the immune status of cows with experimental fasciolosis sensitized by atypical mycobacteria. For the
trial, 15 cows of 4–5 years of age, black and spotted breed, were selected, from which 3 groups were
formed, five animals in each. Cows of the first research group for experimental fasciolosis were injected
intramuscularly with closaverm A at a dose of 0.5 ml of the drug per 10 kg of body weight. The animals of
the second experimental group, for experimental fasciolosis, were intramuscularly injected with closaverm
A at a dose of 0.5 ml of the drug per 10 kg of body weight and butaselmevit at a dose of 10 ml of the drug
per animal. The obtained results indicate that the drugs “Klosaverm A” and “Butaselmevit” when administered
intramuscularly to cows with experimental fasciolosis, sensitized by atypical mycobacteria, contribute
to the activation of cellular and nonspecific links of immunity. It should be noted that a number of our
research also established the stimulating effect of drugs on the humoral link of immunity, in particular, an
increase in the bactericidal and lysozyme activity of blood serum of cows associated with mycobacteriosis
and fasciolosis. Using “Klosaverm A” and “Butaselmevit” drugs in experimental groups of animals helped
reduce the level of CIC to physiological values starting from the 21st day of the experiment. It should be
noted that according to the indicators of the immune system in cows with experimental fasciolosis, sensitized
by atypical mycobacteria, the combined use of closer A and butaselmevit shows a better therapeutic
effect than the use of only closaverm A alone.
